tinidazole has been researched along with Infections, Trichomonas in 34 studies
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.
tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance during pregnancy has not been reported." | 5.37 | A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated. ( Sobel, JD; Subramanian, C, 2011) |
| "Intestinal amoebiasis: of 502 patients, comprising 458 adults and 44 children, with symptomatic intestinal amoebiasis who received tinidazole as a single daily dose on 2 to 3 consecutive days, 477 (95%) were parasitologically cured with complete or marked improvement in symptoms." | 5.26 | Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study. ( Apte, VV; Packard, RS, 1978) |
| "Metronidazole desensitization is recommended in patients with trichomoniasis and history of an allergic reaction to metronidazole due to presumed cross reactivity with tinidazole and lack of reliably safe and effective alternative therapies." | 4.02 | Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole. ( Biagi, M; Slipke, W; Smalley, A; Tsaras, G, 2021) |
| "Tinidazole, a synthetic imidazole derivative, has been used in the oral treatment of several protozoal infections - trichomoniasis, giardiasis and amoebiasis." | 3.65 | Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. ( Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1976) |
| "Tinidazole is a 5-nitroimidazole active in vitro against a wide variety of anaerobic bacteria and protozoa." | 2.45 | [Tinidazole: a classical anaerobical drug with multiple potential uses nowadays]. ( Giménez, MJ; Granizo, JJ; Manso, FJ; Pía Rodicio, M, 2009) |
| "Resistance during pregnancy has not been reported." | 1.37 | A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated. ( Sobel, JD; Subramanian, C, 2011) |
| "Therefore the possibility of trichomoniasis shoudl be taken into account not only when discharge is found in females or persistent urethritis in males, but also in other affections." | 1.26 | [Trichomoniasis. Physiopathology and therapy]. ( Walther, H, 1977) |
| "Intestinal amoebiasis: of 502 patients, comprising 458 adults and 44 children, with symptomatic intestinal amoebiasis who received tinidazole as a single daily dose on 2 to 3 consecutive days, 477 (95%) were parasitologically cured with complete or marked improvement in symptoms." | 1.26 | Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study. ( Apte, VV; Packard, RS, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (55.88) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 6 (17.65) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalleri, B | 1 |
| Volpe, G | 1 |
| Arioli, V | 1 |
| Pizzocheri, F | 1 |
| Diena, A | 1 |
| McNeil, CJ | 1 |
| Williamson, JC | 1 |
| Muzny, CA | 2 |
| Augostini, P | 1 |
| Bradley, ELP | 1 |
| Raphael, BH | 1 |
| Secor, WE | 2 |
| Kissinger, PJ | 1 |
| Biagi, M | 1 |
| Slipke, W | 1 |
| Smalley, A | 1 |
| Tsaras, G | 1 |
| Fernando, HV | 1 |
| Chan, LL | 1 |
| Dang, N | 1 |
| Santhanes, D | 1 |
| Banneheke, H | 1 |
| Nalliah, S | 1 |
| Coombes, AGA | 1 |
| Granizo, JJ | 1 |
| Pía Rodicio, M | 1 |
| Manso, FJ | 1 |
| Giménez, MJ | 1 |
| Mitchell, L | 1 |
| Hussey, J | 1 |
| Schwebke, JR | 2 |
| Rompalo, A | 2 |
| Taylor, S | 1 |
| Seña, AC | 2 |
| Martin, DH | 2 |
| Lopez, LM | 2 |
| Lensing, S | 2 |
| Lee, JY | 2 |
| Subramanian, C | 1 |
| Sobel, JD | 1 |
| Taylor, SN | 1 |
| Zoltán, K | 1 |
| Vargha, P | 1 |
| Czeizel, E | 1 |
| Richter, R | 1 |
| Rossignol, JF | 1 |
| Maisonneuve, H | 1 |
| Cho, YW | 1 |
| Nissen, T | 1 |
| Hofstetter, A | 1 |
| Blenk, H | 1 |
| Walther, H | 2 |
| Kawamura, N | 1 |
| Verges, J | 1 |
| Apte, VV | 1 |
| Packard, RS | 1 |
| Berić, B | 1 |
| Pribicević, V | 1 |
| Djordjević, M | 1 |
| Pavlović, N | 1 |
| Ali, SE | 1 |
| Sawyer, PR | 1 |
| Brogden, RN | 1 |
| Pinder, RM | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Rzempołuch, E | 1 |
| Cwik, F | 1 |
| Szymanska, A | 1 |
| Lubelska, K | 1 |
| Andersen, HJ | 1 |
| Gerstenkorn, T | 1 |
| Kurnatowska, A | 1 |
| Rakus, E | 1 |
| Macicková, T | 1 |
| Kettner, M | 1 |
| Linek, K | 1 |
| Chunge, CN | 1 |
| Estambale, BB | 1 |
| Pamba, HO | 1 |
| Chitayi, PM | 1 |
| Munanga, P | 1 |
| Kangethe, S | 1 |
| Roach, PD | 1 |
| Wallis, PM | 1 |
| Olson, ME | 1 |
| Glukhen'kii, BT | 1 |
| Boiko, IuIa | 1 |
| Bratus', FF | 1 |
| Dellenbach, P | 1 |
| Muller, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized, Placebo-Controlled Double-Blind 4-Arm Trial for the Treatment of Non-Gonococcal Urethritis (NGU): Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)[NCT00322465] | Phase 2 | 305 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit.~Clinical Failure at first follow-up: [Persistent symptoms AND >= 5 PMNs per 3-5 oil immersion fields (regardless of urethral discharge)] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs).~Clinical Failure at second follow-up: >= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)" (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline + (Doxycycline + Tinidazole) | 49 |
| Azithromycin + (Azithromycin + Tinidazole) | 44 |
"Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit.~Clinical Failure at first follow-up: [Persistent symptoms AND >= 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields (regardless of urethral discharge)] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs).~Clinical Failure at second follow-up: >= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)" (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 47 |
| Doxycycline + Tinidazole | 51 |
| Azithromycin | 39 |
| Azithromycin + Tinidazole | 48 |
Microbiological cure of Chlamydia trachomatis refers to the percentage of men with NGU who were negative for Chlamydia trachomatis at the last available result and had been positive for Chlamydia trachomatis at baseline. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 89 |
| Doxycycline + Tinidazole | 75 |
| Azithromycin | 66 |
| Azithromycin + Tinidazole | 61 |
Microbiological Cure of Mycoplasma Genitalium refers to the percentage of men with NGU who were negative for Mycoplasma Genitalium at the last available result and had been positive for Mycoplasma Genitalium at baseline. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 23 |
| Doxycycline + Tinidazole | 32 |
| Azithromycin | 52 |
| Azithromycin + Tinidazole | 68 |
Microbiological cure of Trichomonas vaginalis refers to the percentage of men with NGU who were negative for Trichomonas vaginalis (swab and urine specimens) at the last available result and had been positive for Trichomonas vaginalis at baseline (swab or urine specimen). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 55 |
| Doxycycline + Tinidazole | 75 |
| Azithromycin | 56 |
| Azithromycin + Tinidazole | 50 |
Percentage of men with non-gonococcal urethritis that had a positive result for Chlamydia trachomatis at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment visit)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 50 |
| Doxycycline + Tinidazole | 38 |
| Azithromycin | 38 |
| Azithromycin + Tinidazole | 46 |
Percentage of men with non-gonococcal urethritis that had a positive result for Mycoplasma genitalium at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 29 |
| Doxycycline + Tinidazole | 30 |
| Azithromycin | 32 |
| Azithromycin + Tinidazole | 32 |
Percentage of men with non-gonococcal urethritis that had a positive result for Trichomonas vaginalis from a urethral swab or urine specimen at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment visit)
| Intervention | Percentage of participants (Number) |
|---|---|
| Doxycycline | 14 |
| Doxycycline + Tinidazole | 16 |
| Azithromycin | 12 |
| Azithromycin + Tinidazole | 10 |
At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Participants (Number) |
|---|---|
| Doxycycline | 0 |
| Doxycycline + Tinidazole | 3 |
| Azithromycin | 3 |
| Azithromycin + Tinidazole | 7 |
At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Participants (Number) |
|---|---|
| Doxycycline | 3 |
| Doxycycline + Tinidazole | 4 |
| Azithromycin | 0 |
| Azithromycin + Tinidazole | 4 |
At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Participants (Number) |
|---|---|
| Doxycycline | 6 |
| Doxycycline + Tinidazole | 5 |
| Azithromycin | 3 |
| Azithromycin + Tinidazole | 5 |
At all study visits, unsolicited adverse events were recorded. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Participants (Number) |
|---|---|
| Doxycycline | 1 |
| Doxycycline + Tinidazole | 1 |
| Azithromycin | 1 |
| Azithromycin + Tinidazole | 0 |
At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)
| Intervention | Participants (Number) |
|---|---|
| Doxycycline | 4 |
| Doxycycline + Tinidazole | 2 |
| Azithromycin | 0 |
| Azithromycin + Tinidazole | 0 |
Clinical, behavioral, and demographic variables considered were discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days as well as last 3 months; number of times vaginal sex, oral sex, or anal sex in past 30 days; always/almost always used condom in last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)
| Intervention | Participants (Number) | |
|---|---|---|
| Positive for Chlamydia Trachomatis at Baseline | Negative for Chlamydia Trachomatis at Baseline | |
| All Participants Analyzed | 128 | 162 |
Logistic multiple regression with independent variable selection based on single variable models with p<0.10. Participants positive at enrollment for Mycoplasma genitalium from urine specimen. Potential variables: discharge amount and appearance; condom use last sex; new recent partner, number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)
| Intervention | Participants (Number) | |
|---|---|---|
| Positive for Mycoplasma Genitalium at Baseline | Negative for Mycoplasma Genitalium at Baseline | |
| All Participants Analyzed | 90 | 202 |
Trichomonas vaginalis was determined from urethral swab or urine specimen. Clinical, behavioral, and demographic predictors considered included discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom in last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)
| Intervention | Participants (Number) | |
|---|---|---|
| Positive for Trichomonas Vaginalis at Baseline | Negative for Trichomonas Vaginalis at Baseline | |
| All Participants Analyzed | 38 | 253 |
1 review available for tinidazole and Infections, Trichomonas
| Article | Year |
|---|---|
[Tinidazole: a classical anaerobical drug with multiple potential uses nowadays].
Topics: Anaerobiosis; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antiprotozoal Agents; Bacteria | 2009 |
3 trials available for tinidazole and Infections, Trichomonas
| Article | Year |
|---|---|
Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antiprotozoal Agents; Azithromycin; Chlamydia Infections; | 2011 |
Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antitrichomonal Agents; Azithromycin; Chlamydia Infections | 2012 |
Clinical evaluation of a single dose of tinidazole in trichomoniasis.
Topics: Clinical Trials as Topic; Female; Humans; Nitroimidazoles; Recurrence; Tinidazole; Trichomonas Infec | 1975 |
30 other studies available for tinidazole and Infections, Trichomonas
| Article | Year |
|---|---|
Synthesis and biological activity of new 2-nitroimidazole derivatives.
Topics: Animals; Antitrichomonal Agents; Clostridium perfringens; Drug Interactions; Hexobarbital; Male; Mic | 1978 |
Successful Treatment of Persistent 5-Nitroimidazole-Resistant Trichomoniasis With an Extended Course of Oral Secnidazole Plus Intravaginal Boric Acid.
Topics: Female; Humans; Metronidazole; Tinidazole; Trichomonas Infections; Trichomonas Vaginitis | 2023 |
In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure.
Topics: Drug Resistance; Female; Humans; In Vitro Techniques; Metronidazole; Pharmaceutical Preparations; Ti | 2023 |
Where Do Tinidazole and Secnidazole Fit in With the Treatment of Trichomoniasis?
Topics: Female; Humans; Metronidazole; Nitroimidazoles; Tinidazole; Trichomonas Infections; Trichomonas Vagi | 2023 |
Successful treatment of trichomoniasis with tinidazole following desensitization in a patient allergic to metronidazole.
Topics: Adult; Antitrichomonal Agents; Drug Resistance; Female; Humans; Hypersensitivity; Metronidazole; Tin | 2021 |
Controlled delivery of the antiprotozoal agent (tinidazole) from intravaginal polymer matrices for treatment of the sexually transmitted infection, trichomoniasis.
Topics: Administration, Intravaginal; Antitrichomonal Agents; Chemistry, Pharmaceutical; Crystallization; De | 2019 |
Trichomonas vaginalis: an unusual presentation.
Topics: Adult; Antiprotozoal Agents; Female; Humans; Tinidazole; Treatment Outcome; Trichomonas Infections; | 2010 |
A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated.
Topics: Adult; Anti-Infective Agents; Antitrichomonal Agents; Drug Resistance, Microbial; Female; Humans; Me | 2011 |
Trichomonas vaginalis: treatment questions and challenges.
Topics: Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Antiprotozoal Agents; Drug Resist | 2012 |
Tinidazole (Tindamax) - a new anti-protozoal drug.
Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Child; Child, Preschool; Dose-Response R | 2004 |
[Study of the teratogenic effects of oral tinidazole therapy in pregnancy].
Topics: Abnormalities, Drug-Induced; Administration, Oral; Antitrichomonal Agents; Case-Control Studies; Fem | 2006 |
Conventional therapy of trichomoniasis.
Topics: Antitrichomonal Agents; Female; Gastrointestinal Diseases; Humans; Metronidazole; Ornidazole; Pregna | 1983 |
Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis.
Topics: Amebiasis; Animals; Chemical Phenomena; Chemistry; Cricetinae; Female; Giardiasis; Humans; Metronida | 1984 |
[Single-dose treatment of urogenital trichomoniasis with tinidazole (Simplotan). Pharmacodynamics - pharmacokinetics - clinical aspects].
Topics: Chemical Phenomena; Chemistry; Female; Genital Diseases, Male; Humans; Kinetics; Male; Nitroimidazol | 1983 |
[Therapy of prostato-vesiculitis].
Topics: Anti-Bacterial Agents; Cell Membrane Permeability; Chlamydia; Erythromycin; Genital Diseases, Male; | 1978 |
[Trichomoniasis. Physiopathology and therapy].
Topics: Arthritis; Erythema Nodosum; Female; Humans; Infertility, Female; Male; Tinidazole; Trichomonas Infe | 1977 |
Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men.
Topics: Drug Combinations; Female; Humans; Male; Metronidazole; Nitroimidazoles; Recurrence; Tinidazole; Tri | 1978 |
[Prostatitis due to the circular form of trichomonas (author's transl)].
Topics: Adult; Humans; Infertility, Male; Male; Nimorazole; Prostatitis; Spermatozoa; Tinidazole; Trichomona | 1979 |
Tinidazole in the treatment of trichomoniasis, giardiasis and amoebiasis. Report of a multicentre study.
Topics: Adult; Amebiasis; Child; Dysentery, Amebic; Giardiasis; Humans; Liver Abscess, Amebic; Nitroimidazol | 1978 |
[Clinical studies on the therapeutic effect of tinidazole ("Fasigyn") during treatment of urogenital trichomonas infections in women and men (with comparative laboratory studies on the effect of metronidazole and tinidazole)].
Topics: Adult; Female; Humans; Male; Metronidazole; Nitroimidazoles; Tinidazole; Trichomonas Infections; Tri | 1978 |
[Multicenter study on the treatment of urogenital trichomonas infection using Simplotan].
Topics: Adult; Antiprotozoal Agents; Female; Humans; Male; Nitroimidazoles; Tinidazole; Trichomonas Infectio | 1977 |
Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.
Topics: Abnormalities, Drug-Induced; Amebiasis; Animals; Eukaryota; Giardiasis; Gonorrhea; Humans; Kinetics; | 1976 |
[Therapeutic effectiveness of metronidazole, Fasygin and Pimafucin in trichomoniasis. A comparative study].
Topics: Adolescent; Adult; Female; Humans; Male; Metronidazole; Middle Aged; Natamycin; Nitroimidazoles; Tin | 1976 |
[Treatment of urogenital trichomoniasis with a single dose of tinidazole].
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nitroimidazoles; Tinidaz | 1975 |
[Use of the Fuzzy Set Theory in the diagnosis and treatment of inflammatory conditions of the genital organs and the urinary system in women].
Topics: Candidiasis, Vulvovaginal; Diagnosis, Differential; Female; Humans; Mathematics; Metronidazole; Mode | 1990 |
In vivo effect of 2,4-dinitro-phenyl-substituted sugar hydrazones and phenylosazone against Trichomonas vaginalis and Tritrichomonas foetus.
Topics: Abscess; Acetaldehyde; Animals; Antitrichomonal Agents; Diglycerides; Female; Glycerides; Hydrazones | 1990 |
Pathogenicity of Trichomonas hominis in Kenya.
Topics: Acute Disease; Adolescent; Adult; Animals; Child; Diarrhea; Female; Humans; Kenya; Male; Tinidazole; | 1988 |
The use of metronidazole, tinidazole and dimetridazole in eliminating trichomonads from laboratory mice.
Topics: Animals; Dimetridazole; Male; Metronidazole; Mice; Nitroimidazoles; Rodent Diseases; Tinidazole; Tri | 1988 |
[Results of treating trichomoniasis in women with tinidazole].
Topics: Adolescent; Adult; Female; Humans; Middle Aged; Nitroimidazoles; Tinidazole; Trichomonas Infections | 1986 |
[Treatment of urogenital trichomoniasis with Fasigyn].
Topics: Female; Humans; Nitroimidazoles; Tinidazole; Trichomonas Infections; Trichomonas Vaginitis; Urinary | 1972 |